Motives and side-effects of microdosing with psychedelics among users
Surveying 1,116 psychedelic users, the study found most microdosed with LSD or psilocybin—typically 2–4 times weekly—primarily to enhance performance and commonly experienced acute psychological side‑effects while under the influence, with many stopping because they perceived no benefit. The authors conclude that placebo‑controlled experimental studies are needed to quantify any performance enhancement and assess longer‑term harms.
Authors
- Patrick Dolder
- Kim Kuypers
- Nathalie Mason
Published
Abstract
Background
Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects.
Methods
An online questionnaire was launched on several websites and fora between March and July 2018. Respondents who had consented, were 18 years of age or older, and had experience with microdosing were included in the analyses.
Results
In total, 1116 of the respondents were either currently microdosing (79.5%) or microdosed in the past (20.5%). Lysergic acid diethylamide (10 mcg) and psilocybin (0.5 g) were the most commonly used psychedelics with a microdosing frequency between 2 and 4 times per week. The majority of users, however, were oblivious about the consumed dose. Performance enhancement was the main motive to microdose (37%). The most reported negative effects were of psychological nature and occurred acutely while under the influence.
Conclusion
In line with media reports and anecdotes, the majority of our respondents microdosed to enhance performance. Negative effects occurred mostly acutely after substance consumption. However, the main reason to have stopped microdosing was that it was not effective. Future experimental placebo-controlled studies are needed to test whether performance enhancement can be quantified and to assess potential negative effects after longer term microdosing.
Research Summary of 'Motives and side-effects of microdosing with psychedelics among users'
Introduction
Microdosing, defined as repeatedly taking a low dose of psychedelics such as LSD or psilocybin without inducing overt perceptual changes, has received substantial media attention as a putative performance enhancer. Earlier research on low doses exists but is limited, and key features of current microdosing practice — including exact doses, schedules, prevalence across substances and workplaces, motives, and possible adverse effects — remain incompletely characterised. Small placebo-controlled laboratory studies have so far produced mixed or null findings on some subjective outcomes, and anecdotal reports dominate public discourse. Hutten and colleagues set out to address this gap by conducting an online questionnaire survey of people with psychedelic experience to quantify lifetime psychedelic use, microdosing practices (dose, frequency, route and how schedules were obtained), motives for microdosing, prevalence of microdosing at work, and the occurrence and timing of negative effects. The stated aim was descriptive: to provide detailed user-reported data that can inform future experimental and clinical investigations of efficacy and safety of microdosing.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topic
- Authors
- APA Citation
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019). Motives and side-effects of microdosing with psychedelics among users. International Journal of Neuropsychopharmacology, 22(7), 426-434. https://doi.org/10.1093/ijnp/pyz029
References (9)
Papers cited by this study that are also in Blossom
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Horsley, R. R., Páleníček, T., Kolin, J. et al. · Behavioural Pharmacology (2018)
Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)
Liechti, M. E. · Neuropsychopharmacology (2017)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Yanakieva, S., Polychroni, N., Family, N. et al. · Psychopharmacology (2018)
Cited By (32)
Papers in Blossom that reference this study
Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L. et al. · Therapeutic Advances in Psychopharmacology (2025)
Cavarra, M., Hutten, N. R. P. W., Schepers, J. et al. · British Journal of Pain (2025)
Modzelewski, S., Waszkiewicz, N., Lukasiewicz, K. et al. · Neuropharmacology (2025)
Syed, O. A., Petranker, R., Fewster, E. C. et al. · Journal of Psychoactive Drugs (2024)
Oblak, A., Korošec Hudnikr, L., Levačić, A. et al. · OSF Preprints (2024)
Murray, C., Frohlich, J, Haggarty, C. J., Tare, I. et al. · Neuropsychopharmacology (2024)
Murphy, R., Sumner, R. L., Evans, W. J. et al. · Biological Psychiatry (2023)
Tagen, M., Mantuani, D., Van Heerden, L. et al. · Journal of Psychopharmacology (2023)
Ryan, R. S., Copello, A., Fox, A. P. · BMC Psychiatry (2023)
Kinderlehrer, D. A. · International Medical Case Reports Journal (2023)
Show all 32 papersShow fewer
Pop, I., Dinkelacker, J. · Journal of Psychedelic Studies (2023)
Kaypak, A. C., Raz, A. · Transcultural Psychiatry (2022)
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)
Rootman, J. M., Kiraga, M., Kryskow, P. et al. · Scientific Reports (2022)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)
Barker, S. A. · Psychopharmacology (2022)
Haijen, E., Hurks, P. P. M., Kuypers, K. P. C. · Neuroscience Applied (2022)
Polito, V., Liknaitzky, P. · Psyarxiv (2021)
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2021)
Rootman, J. M., Kryskow, P., Harvey, K. et al. · Scientific Reports (2021)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Klein, A. K., Chatha, M., Laskowski, L. J. et al. · ACS Pharmacology and Translational Science (2020)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)
Zhang, D. Z., Holze, F., Liechti, M. E. et al. · Clinical Pharmacology and Therapeutics (2020)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)
Bornemann, J. · Journal of Psychoactive Drugs (2020)
Rosenbaum, D., Weissman, C. R., Anderson, T. et al. · Journal of Psychopharmacology (2020)
Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · Frontiers in Psychiatry (2019)
Beaton, B., Copes, H., Webb, M. et al. · Journal of Drug Issues (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.